Evidence map›Paper›PMID 35377924›Full record

ArticlePLoS pathogens2022

NK cells and monocytes modulate primary HTLV-1 infection.

Ramona Moles, Sarkis Sarkis, Veronica Galli, Maria Omsland, Maria Artesi, Massimiliano Bissa, Katherine McKinnon, Sophia Brown, Vincent Hahaut, Robyn Washington-Parks and 12 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  9. Complete Rescue of HTLV-1Pathogens (Basel, Switzerland) · 2024
    Article
  10. Intercellular Transport of Viral Proteins.Results and problems in cell differentiation · 2024
    Review
  11. HTLV-1 Proliferation after CD8Microbiology spectrum · 2023
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 3 countries.

Ramona MolesAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0001-8576-2394
Sarkis SarkisAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Veronica GalliAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Maria OmslandAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0002-0818-6490
Maria ArtesiLaboratory of Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Massimiliano BissaAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0003-3455-3992
Katherine McKinnonVaccine Branch Flow Cytometry Core, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Sophia BrownVaccine Branch Flow Cytometry Core, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0001-5782-8755
Vincent HahautLaboratory of Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Robyn Washington-ParksAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0002-5284-9765
Joshua WelshTranslational Nanobiology Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0002-1097-9756
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0002-8990-158X
Anna GutowskaAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Melvin N DosterAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Matthew W BreedLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, Maryland, United States of America.
Kristin E KilloranLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, Maryland, United States of America.ORCID 0000-0002-5400-1231
Joshua KramerLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, Maryland, United States of America.
Jennifer JonesTranslational Nanobiology Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0002-9488-7719
Marcin MoniuszkoDepartment of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Anne Van den BroekeLaboratory of Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-5422-0549
Cynthia A Pise-MasisonAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0003-2788-235X
Genoveffa FranchiniAnimal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID 0000-0003-2851-6589
National Cancer Institute · USLeidos (United States) · USUniversité Libre de Bruxelles · BENational Institutes of Health · USMedical University of Białystok · PL

Funding

T-cell Transformation by OncovirusesZIABC005645 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRANCHINI, GENOVEFFA · 2009 to 2025
$14.1M
CCR VB FACS COREZICBC010936 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCKINNON, KATHERINE · 2009 to 2025
$10.9M
Novel Combinations of Radiation and ImmunotherapyZIABC011503 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2013 to 2025
$5.3M
6 · The paper itself

Abstract

We investigated the impact of monocytes, NK cells, and CD8+ T-cells in primary HTLV-1 infection by depleting cell subsets and exposing macaques to either HTLV-1 wild type (HTLV-1WT) or to the HTLV-1p12KO mutant unable to infect replete animals due to a single point mutation in orf-I that inhibits its expression. The orf-I encoded p8/p12 proteins counteract cytotoxic NK and CD8+ T-cells and favor viral DNA persistence in monocytes. Double NK and CD8+ T-cells or CD8 depletion alone accelerated seroconversion in all animals exposed to HTLV-1WT. In contrast, HTLV-1p12KO infectivity was fully restored only when NK cells were also depleted, demonstrating a critical role of NK cells in primary infection. Monocyte/macrophage depletion resulted in accelerated seroconversion in all animals exposed to HTLV-1WT, but antibody titers to the virus were low and not sustained. Seroconversion did not occur in most animals exposed to HTLV-1p12KO. In vitro experiments in human primary monocytes or THP-1 cells comparing HTLV-1WT and HTLV-1p12KO demonstrated that orf-I expression is associated with inhibition of inflammasome activation in primary cells, with increased CD47 "don't-eat-me" signal surface expression in virus infected cells and decreased monocyte engulfment of infected cells. Collectively, our data demonstrate a critical role for innate NK cells in primary infection and suggest a dual role of monocytes in primary infection. On one hand, orf-I expression increases the chances of viral transmission by sparing infected cells from efferocytosis, and on the other may protect the engulfed infected cells by modulating inflammasome activation. These data also suggest that, once infection is established, the stoichiometry of orf-I expression may contribute to the chronic inflammation observed in HTLV-1 infection by modulating monocyte efferocytosis.

Indexed as

HTLV-I InfectionsHuman T-lymphotropic virus 1AnimalsInflammasomesKiller Cells, NaturalMonocytesInflammasomes

Identifiers

PMID35377924
PMCPMC9022856
OpenAlexW4224309507

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.